Navidea Biopharma (NAVB) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Navidea Biopharmaceuticals Reports Third Quarter and Year-to-Date 2020 Financial Results
November 12, 2020 4:02 PM ESTConference Call to be held Thursday, November 12, 2020 at 5:00 pm EST
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter and year-to-date for the period ended September 30, 2020.
Navidea continues to build on its clinical momentum and this quarter fully shows our ability to execute during a very trying time globally, said Mr. Jed A. Latkin, Chief Executive Officer of Navidea. The due diligence continues... More
